Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178281 · ClinicalTrials.gov registry record · Phase 3
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
A Phase 3 study of Primary Myelofibrosis and MPN-associated Myelofibrosis, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 267
- Enrollment target
- 20
- Study locations
NCT01178281: Completed Phase 3 study of Primary Myelofibrosis and MPN-associated Myelofibrosis, sponsored by Celgene.
NCT01178281 is a Phase 3 study of Primary Myelofibrosis and MPN-associated Myelofibrosis that has completed, run by Celgene. The registered enrollment target is 267 participants, above the 112-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (138% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01178281, a Phase 3 study of Primary Myelofibrosis and MPN-associated Myelofibrosis, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 267 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global study) and in reversing anemia in Chinese with MPN-associated myelofibrosis and severe anemia not receiving RBC-transfusions (China extension study only)
Primary Outcome
RBC-transfusion independence was defined as the absence of RBC transfusions for any consecutive 84-day interval.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pomalidomide
- DRUG Pomalidomide 0.5 mg
Study Locations (20)
New York
- Mount Sinai School of Medicine Brookdale University Hospital - Brooklyn
- Weill Medical College of Cornell University - New York
- Ruttenberg Treatment Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- University of Florida Shands Cancer Center - Gainesville
- Mayo Clinic - Jacksonville
New South Wales
- Gosford Hospital - Gosford
- Royal North Shore Hospital - St Leonards
Arizona
- Mayo Clinic - Scottsdale
California
- UCLA School of Medicine - Los Angeles
Illinois
- University of Illinois at Chicago - Chicago
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2010-09-08 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 3 |
What the finished NCT01178281 record still lists
NCT01178281 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, above the 112-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (138% higher).
The record links to 2 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01178281 names 20 study sites across 15 states, led by New York, Florida, New South Wales.
Frequently Asked Questions
What is clinical trial NCT01178281 about?
NCT01178281 is a clinical study titled "Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence". The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global study) and in reversing anemia in Chinese with MPN-associated myelofibros...
What is the current status of trial NCT01178281?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 267 participants. The study started on 2010-09-08. Estimated completion is 2018-05-15.
What conditions does trial NCT01178281 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, MPN-associated Myelofibrosis.
What interventions are being tested in trial NCT01178281?
The interventions under investigation include: Placebo (DRUG), Pomalidomide (DRUG), Pomalidomide 0.5 mg (DRUG).
Who is sponsoring clinical trial NCT01178281?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01178281 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01178281's enrollment target sits among peer trials
267 6th of 30 higher than 25 of 30 other Primary Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
RECRUITING · Phase 3
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
ACTIVE NOT RECRUITING · Phase 3
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI